Canagliflozin vs GDF-11
A side-by-side research comparison of Canagliflozin and GDF-11 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Canagliflozin | GDF-11 |
|---|---|---|
| Full name | Canagliflozin (SGLT2 Inhibitor) | Growth Differentiation Factor 11 |
| Category | Anti-Aging | Anti-Aging |
| Status | FDA-approved drug | Research compound |
| Mechanism | Blocks the sodium-glucose cotransporter 2 in the kidney, causing excess glucose to be excreted in urine. This lowers blood glucose independent of insulin, reduces blood pressure and weight, and produces cardio-renal protective effects. | Signals through activin type II receptors and SMAD2/3 to restore stem cell function, promote neurogenesis, and improve vascular remodeling in the context of aging. |
| Molecular weight | 444.52 Da | 12,500 Da |
| Half-life | ~11-13 hours | 6-8 hours |
| Bioavailability | ~65% oral | Moderate (SubQ/IV) |
| Typical dose | 100-300 mg per day | 0.1-0.5 mg/kg (research) |
| Frequency | Once daily | Daily (animal studies) |
| Route | Oral tablet | Subcutaneous |
Canagliflozin reported benefits
- Insulin-independent glucose lowering
- Cardiovascular protection
- Kidney protection
- Blood pressure reduction
- Weight loss
- Longevity signal (ITP data)
GDF-11 reported benefits
- Potential tissue rejuvenation
- Neurogenesis stimulation
- Cardiac hypertrophy reversal
- Muscle stem cell activation
- Vascular remodeling
Related comparisons
Research and educational reference only. Not medical advice.